Abstract
EE375 Cost-Effectiveness Analysis of the Oncotype DX® Test to Reduce Under-Treatment in Patients With HR+/HER2- Node Negative Early-Stage Breast Cancer and Grade 2 T1C Tumours
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
